IPO registrations (S-1, F-1) · Registrants
CHINOOK THERAPEUTICS, INC.
- SEC CIK
- 1435049 · filings on EDGAR ↗
- Name on the registration
- ADURO BIOTECH, INC.
- Former names
- ADURO BIOTECH, INC. (2011–2020); ADURO BIOTECH (2008–2011)
- Registration
- Form S-1, first filed 2015-03-11, last 2015-04-14; 1 initial registration, 2 amendments
- Outcome
- Final prospectus filed 2015-04-15; declared effective 2015-04-14
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- DE
- Business address
- 400 FAIRVIEW AVENUE NORTH, SUITE 900, Seattle, WA 98109
- EDGAR entity type
- operating
- Insiders and CEO pay
- CHINOOK THERAPEUTICS, INC. on the corporate pages
Offering terms
- Final price
- $17.00 per share (424B4 filed 2015-04-15, an initial public offering)
- Shares sold
- 7,000,000
- Gross proceeds
- $119,000,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol ADRO
- Lead underwriters
- Merrill Lynch; Leerink Partners (2,275,000 shares)
- Syndicate
- BofA Securities; William Blair (1,225,000); Canaccord Genuity (700,000)
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Form D issuer: ADURO BIOTECH, INC. EXACT (CIK (EXACT))
- SEC filer: ADURO BIOTECH, INC. EXACT (CIK (EXACT))
Filings 6
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2015-03-11 | S-1 | S-1 (registration) | ADURO BIOTECH, INC. | 0001193125-15-087572 ↗ |
| 2015-04-06 | S-1/A | S-1/A (amendment) | ADURO BIOTECH, INC. | 0001193125-15-119482 ↗ |
| 2015-04-14 | S-1/A | S-1/A (amendment) | ADURO BIOTECH, INC. | 0001193125-15-128339 ↗ |
| 2015-04-14 | EFFECT | EFFECT (declared effective) | ADURO BIOTECH, INC. | 9999999995-15-000865 ↗ |
| 2015-04-15 | 424B4 | 424B4 (final prospectus) | ADURO BIOTECH, INC. | 0001193125-15-131360 ↗ |
| 2016-05-09 | EFFECT | EFFECT (declared effective) | ADURO BIOTECH, INC. | 9999999995-16-004590 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2015-04-14 | S-1/A | registration statement | $17.00 | 7,000,000 | $119,000,000 | Nasdaq ADRO | 6 | primary document; price sentence, shares headline, proceeds computed, underwriting table 1, cover names 4 | document ↗ | |
| 2015-04-15 | 424B4 | final prospectus | $17.00 | 7,000,000 | $119,000,000 | Nasdaq ADRO | 5 | primary document; price sentence, shares headline, proceeds table, underwriting table 3, cover names 4 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Brockstedt Dirk G. | Officer | EVP of Research and Dev.; Sr. VP of Research and Dev. | 26 | 2015–2018 | |
| Chan Gerald | Director | 5 | 2015–2018 | ||
| Dubensky Thomas W. | Officer | Chief Scientific Officer | 22 | 2015–2017 | |
| Greenman William Mariner | Director | 16 | 2015–2023 | ||
| Haghighat Ross | Director | 16 | 2015–2023 | ||
| ISAACS STEPHEN T | Director,Officer | President and CEO | 47 | 2015–2020 | |
| Lew Jennifer | Officer | Chief Financial Officer; Sr. Vice President of Finance | 28 | 2015–2019 | |
| MCCORMICK FRANK | Director | 5 | 2015–2018 | ||
| Morningside Venture (VI) Investments Ltd | TenPercentOwner | 4 | 2015–2018 | ||
| OBrien Stephanie Monaghan | Director | 8 | 2015–2020 | ||
| Rogers John E. and Lois A. | TenPercentOwner | 4 | 2015 | ||
| SCHAFER GREGORY W | Officer | Chief Operating Officer | 23 | 2015–2018 | |
| Ultimate Keen Ltd | TenPercentOwner | 2 | 2015 | ||
| SHERWIN STEPHEN A | Director | 7 | 2015–2020 | ||
| Templeman Blaine | Officer | Chief Legal Officer; Executive VP, General Counsel; See Remarks | 27 | 2015–2020 | |
| Sacks Natalie | Officer | Chief Medical Officer | 9 | 2016–2018 | |
| van Elsas Andrea | Officer | Chief Scientific Officer | 21 | 2017–2020 | |
| Hoth Daniel Floyd JR | Officer | Interim Chief Medical Officer | 1 | 2018 | |
| Ferber Celeste | Officer | SVP, GC and Secretary | 9 | 2019–2020 | |
| Mack David Henry | Director | 4 | 2019–2020 | ||
| KARBE FRANK | Director | 5 | 2019–2020 | ||
| Nuyten Dimitry SA | Officer | Chief Medical Officer | 5 | 2019–2020 | |
| WELCH JAMES H | Officer | See Remarks | 2 | 2019 | |
| Kachioff William G | Officer | Interim CFO; See Remarks | 2 | 2020 | |
| AKKARAJU SRINIVAS | Director | 9 | 2020–2023 | ||
| DOBMEIER ERIC | Director,Officer | President, CEO | 23 | 2020–2023 | |
| Frohlich Tom | Officer | Chief Business Officer; Chief Operating Officer | 17 | 2020–2023 | |
| Glicklich Alan | Officer | Chief Medical Officer | 6 | 2020–2022 | |
| GRIFFIN MICHELLE RENEE | Director | 6 | 2020–2023 | ||
| Jerel Davis | Director; Director,TenPercentOwner | 15 | 2020–2023 | ||
| King Andrew James | Officer | Chief Scientific Officer; Head of Renal Discovery | 21 | 2020–2023 | |
| Thomas Dolca | Director | 7 | 2020–2023 | ||
| Versant Venture Capital VII, L.P. | TenPercentOwner | 4 | 2020–2022 | ||
| Versant Voyageurs I, L.P. | TenPercentOwner | 4 | 2020–2022 | ||
| Versant Voyageurs I Parallel, L.P. | TenPercentOwner | 4 | 2020–2022 | ||
| BJERKHOLT ERIC | Officer | Chief Financial Officer | 10 | 2020–2023 | |
| Krishnan Mahesh | Director | 4 | 2022–2023 | ||
| Oxtoby Andrew | Officer | Chief Commercial Officer | 3 | 2023 | |
| Azelby Robert | Director | 3 | 2023 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2015-01-05 | ADURO BIOTECH, INC. | Biotechnology | $51,388,002 | $51,388,002 | 28 | 1 |
| 2014-06-13 | ADURO BIOTECH, INC. | Biotechnology | $40,602,333 | $40,602,333 | 25 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Form D issuer | ADURO BIOTECH, INC. | CA | Form D private offerings | CIK (EXACT) |
| Patent assignee | Chinook Therapeutics, Inc. | WA | Patents (USPTO) | name and state |
| SEC filer | CHINOOK THERAPEUTICS, INC. | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | CHINOOK THERAPEUTICS, INC. | WA | Trademarks (USPTO) | name and state |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Pharmaceutical Preparations, WA first:
- PATHOGENESIS CORP WA
- DENDREON CORP WA
- CORUS PHARMA INC WA
- CytoDyn Inc. WA
- OMEROS CORP WA
- Trubion Pharmaceuticals, Inc WA
- Light Sciences Oncology Inc WA
- Cocrystal Pharma, Inc. WA
- ALDER BIOPHARMACEUTICALS INC WA
- PHASERX, INC. WA
In other datasets, the same topic (Health) in WA:
- Nonprofit: ACUPUNCTURE RELIEF PROJECT (Nonprofits (IRS Form 990))
Interests: Pharmaceutical Preparations · Health